V

    Voyager Therapeutics Inc (VYGR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.45
    -0.09 (-2.54%)

    Market Cap: $218.13M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(26/40)
    Avg Surprise
    +53.90%
    Streak
    4 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.42
    Range$-0.80 - $-0.28
    10 analysts
    EPS Revisions
    3
    0
    7d
    3
    0
    30d
    EPS Estimate Drift
    90d ago$-0.48-16.0%
    60d ago$-0.48-16.0%
    30d ago$-0.48-13.6%
    7d ago$-0.48-13.6%
    Current$-0.42
    Revenue Consensus
    $6M
    Range$31000 - $15M
    11 analysts
    Dec 31, 2026
    EPS Consensus$-0.24
    Range$-1.16 - $0.22
    10 analysts
    Revenue Consensus
    $574830
    Range$-7900880 - $30M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.24---
    Sep 26EST
    		-$-0.42---
    Jun 26
    		$-0.40$-0.55+27.27%Beat+29.8%
    Mar 26
    		$-0.47$-0.53+11.32%Beat+11.3%
    Dec 25
    		$-0.47$-0.51+7.93%Beat+20.3%
    Sep 25
    		$-0.47$-0.52+9.62%Beat-193.7%
    Jun 25
    		$-0.57$-0.52-9.62%Miss-216.7%
    Mar 25
    		$-0.53$-0.44-20.45%Miss-165.0%
    Dec 24
    		$-0.59$-0.35-68.43%Miss-147.2%
    Sep 24
    		$-0.16N/A+60.00%Beat+72.9%
    Jun 24
    		$-0.18N/A+55.00%Beat+64.7%
    Mar 24
    		$-0.20N/A+52.38%Beat-106.8%
    Dec 23
    		$1.25$-0.29+531.03%Beat+304.9%
    Sep 23
    		$-0.59$-0.60+1.67%Beat-231.1%
    Jun 23
    		$-0.51$-0.56+8.93%Beat-2.0%
    Mar 23
    		$2.94$1.26+133.33%Beat+625.0%
    Dec 22
    		$-0.61$-0.55-10.91%Miss-506.7%
    Sep 22
    		$0.45$-0.41+209.76%Beat+167.2%
    Jun 22
    		$-0.50$-0.42-19.05%Miss+37.5%
    Mar 22
    		$-0.56$-0.34-64.71%Miss+3.4%
    Dec 21
    		$0.15N/A+145.45%Beat+134.9%
    Sep 21
    		$-0.67$-0.73+8.22%Beat-129.5%
    Jun 21
    		$-0.80$-0.68-17.65%Miss-247.8%
    Mar 21
    		$-0.58$-0.66+12.12%Beat+12.1%
    Dec 20
    		$-0.43$-0.57+24.56%Beat-26.5%
    Sep 20
    		$2.27$0.20+1035.00%Beat+653.7%
    Jun 20
    		$-0.23N/A+66.67%Beat-179.3%
    Mar 20
    		$-0.66$-0.81+18.52%Beat+18.5%
    Dec 19
    		$-0.34N/A+58.02%Beat+51.4%
    Sep 19
    		$-0.41$-0.67+38.81%Beat+34.9%
    Jun 19
    		$0.29N/A+136.25%Beat+136.3%
    Mar 19
    		$-0.81$0.58-239.66%Miss-28.6%
    Dec 18
    		$-0.70$-0.71+1.41%Beat-75.0%
    Sep 18
    		$-0.63$-0.76+17.11%Beat+29.2%
    Jun 18
    		$-0.80$-0.66-21.21%Miss-9.6%
    Mar 18
    		$-0.63$-0.61-3.28%Miss+3.1%
    Dec 17
    		$-0.40$-0.72+44.44%Beat+29.8%
    Sep 17
    		$-0.89$-0.71-25.35%Miss-154.3%
    Jun 17
    		$-0.73$-0.59-23.73%Miss-
    Mar 17
    		$-0.65$-0.53-22.64%Miss-
    Dec 16
    		$-0.57$-0.45-26.67%Miss-
    Sep 16
    		$-0.35$-0.41+14.63%Beat-

    Key Metrics

    Valuation
    P/E Ratio-1.91EV/EBITDA2.59x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-834.00%
    ROE-54.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio7.51xQuick Ratio7.51x
    Trading Statistics
    Beta1.31Avg Volume441.22K
    52-Week High$5.5552-Week Low$2.94

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.42
    SMA 20$3.31
    SMA 50$3.33
    SMA 200$3.79
    EMA 10$3.42
    EMA 20$3.35
    EMA 50$3.37
    EMA 200$3.67

    MACD

    Line: 0.06Signal: 0.03Hist: 0.03

    ADX

    ADX: 13.7+DI: 16.3-DI: 16.1

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down20.0
    PSAR$3.23

    Bollinger Bands

    Upper Band$3.58
    Lower Band$3.04
    %B Position1646%(Upper)
    Band Width0.76

    RSI (14-Day)

    Neutral
    57.0

    Momentum Oscillators

    Stoch %K82.0
    Stoch %D81.9
    Williams %R-25.9
    ROC (10d)6.8%
    Momentum0.22
    CCI (20d)80.6
    MFI (14d)76.5

    Volatility Measures

    ATR (14d)$0.16(4.6%)
    StdDev (20d)0.14
    Hist Vol33.8%(Moderate)

    Volume Flow

    VWAP$3.44
    OBV13.3M
    AD Line-11.3M
    CMF (20d)0.117

    Volume Metrics

    Avg Vol (20d)432.8K
    Vol Ratio0.9x
    VWMA (20d)$3.30

    Pivot Points

    R3$3.81
    R2$3.68
    R1$3.61
    Pivot Point$3.48
    S1$3.42
    S2$3.29
    S3$3.22

    Advanced Oscillators

    TSI13.60
    Ultimate Osc62.5
    KST56.77

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$3.17M$2.59M$15.34M$13.37M$5.20M$6.47M$6.28M$24.63M$29.58M$19.52M$90.06M$4.61M
    Cost of Revenue$0$0$1.05M$0$0$0$32.81M$0$0$0$1.33M$0
    Gross Profit$3.17M$2.59M$15.34M$13.37M$5.20M$6.47M$6.28M$24.63M$29.58M$19.52M$90.06M$4.61M
    Operating Expenses$29.56M$32.86M$45.27M$43.96M$41.83M$41.17M$44.58M$38.41M$44.60M$35.70M$36.00M$34.12M
    R&D$22.04M$24.60M$35.95M$35.87M$31.33M$31.53M$35.58M$30.24M$34.45M$27.09M$25.76M$25.86M
    SG&A$7.52M$8.26M$9.32M$8.09M$10.49M$9.64M$8.99M$8.17M$10.15M$8.61M$10.24M$8.26M
    Operating Income$-26,392,000$-30,270,000$-29,932,000$-30,594,000$-36,625,000$-34,693,000$-38,299,000$-13,780,000$-15,025,000$-16,183,000$54.06M$-29,507,000
    Interest Income$1.53M$1.91M$2.11M$2.38M$2.83M$3.29M$3.99M$4.58M$4.89M$4.87M$3.15M$3.43M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-24,453,000$-27,923,000$-27,417,000$-27,809,000$-33,367,000$-30,984,000$-33,903,000$-9,001,000$-10,117,000$-11,316,000$57.22M$-26,078,000
    Income Tax Expense$20,000$14,000$9,000$83,000$15,000$37,000$584,000$43,000$24,000$14,000$822,000$-177,000
    Net Income$-24,473,000$-27,937,000$-27,426,000$-27,892,000$-33,382,000$-31,021,000$-34,487,000$-9,044,000$-10,141,000$-11,330,000$56.40M$-25,901,000
    EBITDA$-25,321,000$-29,268,000$-29,009,000$-29,916,000$-35,924,000$-34,259,000$-38,399,000$-14,509,000$-16,077,000$-16,918,000$53.60M$-30,369,000
    EBIT$-25,981,000$-29,835,000$-29,528,000$-30,194,000$-36,198,000$-34,275,000$-37,897,000$-13,580,000$-15,005,000$-16,183,000$54.06M$-29,507,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VYGR

    News

    Armistice Capital (VYGR) files 13G/A showing 3.44M Voyager Therapeutics shares

    Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G/A, reporting a beneficial ownership of 3,436,000 shares of Voyager Therapeutics, Inc. (VYGR) common stock, which represents 5.58% of the class. They hold shared voting and dispositive power over these shares, which are directly held by Armistice Capital Master Fund Ltd. This filing indicates a moderate impact and neutral sentiment.

    Stock Titan•8/14/26•
    Neutral

    Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47%

    Analysts have significantly cut their revenue estimates for Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 47% for the current year, now projecting US$21 million for 2026, a 40% decline from the previous year. The revised forecast also anticipates a slight increase in loss per share to US$1.68. This negative revision is noteworthy as the company's revenue is expected to decline faster than the overall industry, leading to increased caution among investors.

    Sahm•8/13/26•
    Bearish

    Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47%

    Analysts have significantly revised down their revenue estimates for Voyager Therapeutics, Inc. (NASDAQ:VYGR) for 2026 by 47%, now expecting US$21 million, a 40% decline from the previous year. Concurrently, loss per share estimates have increased. This downgrade reflects a more conservative outlook for the company's financial performance, forecasting a faster decline in sales compared to the broader industry.

    Simply Wall Street•8/12/26•
    Bearish

    Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47%

    Analysts have significantly revised down their revenue forecasts for Voyager Therapeutics (NASDAQ:VYGR) by 47% for 2026, now expecting US$21m, a 40% decline from last year. The consensus also anticipates a slight increase in loss per share to US$1.68. This downgrade suggests a more conservative outlook from analysts, with the company's sales growth expected to underperform the broader industry.

    Simply Wall Street•8/12/26•
    Bearish

    Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright

    HC Wainwright reaffirmed its "Buy" rating for Voyager Therapeutics (NASDAQ:VYGR), contributing to a "Moderate Buy" consensus and a $16.50 price target from analysts. The company reported adjusted quarterly losses of $0.40 per share, surpassing estimates, but revenue of $3.17 million fell short of expectations. Institutional investors own 48.03% of the outstanding shares, with the stock opening at $3.27 and a market capitalization of approximately $197.6 million.

    MarketBeat•8/10/26•
    Somewhat-Bullish

    Frequently Asked Questions About VYGR

    Does VYGR pay dividends?
    Voyager Therapeutics Inc (VYGR) does not currently pay a regular dividend.
    What is VYGR's market cap?
    Voyager Therapeutics Inc (VYGR) has a market capitalization of $218.13M with a current stock price of $3.45.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In